LI Juan, SU Yun, ZHANG Yi, et al. Effects of Hedysari Radix Flavonoids in Different Time Points on Angiogenesis Index in Pulmonary Interstitial Fibrosis Rat Model[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(3): 129-132.
LI Juan, SU Yun, ZHANG Yi, et al. Effects of Hedysari Radix Flavonoids in Different Time Points on Angiogenesis Index in Pulmonary Interstitial Fibrosis Rat Model[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(3): 129-132. DOI: 10.11653/syfj2014030129.
Objective: To study the effect of Hedysari Radix flavonoids in different time points on angiogenesis index in the pulmonary interstitial fibrosis rat model. Method: Hundred and forty-four SPF Wistar rats were distributed to blank group
model group
prednisone group
Hedysari Radix flavonoids high
middle
low dose groups by bleomycin intratracheal instillation method to establish the model of pulmonary fibrosis. From the second day after modeling
the corresponding drugs were given to each group
ig for 14 days or 28 days. Immunohistochemistry method was used to observe the expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR2). Result: Model groups 14
28 days VEGF and VEGFR2 increased significantly when compared with the control group.Compared with 14 d model group
high dose flavonoids group in VEGF and VEGFR2 expression decreased (P<0.05). Compared with 28 d model group
high dose flavonoids group in VEGF and VEGFR2 expression decreased significantly (P<0.05). Fourteen
28 d low dose groups had no significant difference with the 28 d model group
in VEGF and VEGFR2 expression. 14
28 d middle dose groups in expression of VEGF and VEGFR2 were between 14
28 d high dose group and low dose group
and had no statistical significance with 14 d
28 d model group. Conclusion: The anti fibrosis mechanism of Hedysari Radix flavonoids was probably through inhibiting angiogenesis related factor VEGF and VEGFR2 to inhibit the formation of pathological angiogenesis resulting in the delayed pulmonary fibrosis.